SpringWorks, Eli Lilly and More Release Data Ahead of ESMO

SpringWorks Therapeutics plans to share new data from its Phase III DeFi trial evaluating nirogacestat in adult patients with progressing desmoid tumors. The data will be presented as part of a late-breaking abstract.